In Focus: As Lyrica profits dry up, Northwestern seeks another ‘blockbuster’ drug

Northwestern boasts some of the deepest pockets of any university in the country. Its more than $10 billion in net assets is the product of many factors — wealthy donors, pricey tuition, shrewd investments. But one of the largest reasons for the University’s wealth is Lyrica, a pharmaceutical used to treat fibromyalgia, epilepsy and other conditions.